Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Author's Avatar
Jul 03, 2022

-Data anticipated in Q3 2022-